Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.91 USD
Change Today -0.11 / -1.00%
Volume 1.5M
NKTR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Gil M. Labrucherie J.D.

Senior Vice President, General Counsel and Secretary, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

42$1,478,488
As of Fiscal Year 2013

Background*

Mr. Gil M. Labrucherie, J.D. has been General Counsel and Senior Vice President of Nektar Therapeutics since April 2, 2007. Mr. Labrucherie has been Secretary of Nektar Therapeutics since April 2, 2007. He serves as Secretary of Senova Systems, Inc. He served as Interim Secretary of Chadmoore Wireless Group Inc. (formerly, Capvest Internationale Ltd.) since November 10, 2006 and as its Interim President from November 10, 2006 to March 26, 2007. Mr. Labrucherie served ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

Co-Founder and Secretary
2002-N/A
Former Chairman and Interim Secretary

Education*

BA
University of California, Davis
JD
University of California-berkeley School of Law

Other Affiliations*

Annual Compensation*

Salary$504,195
Total Annual Compensation$504,195

Stock Options*

All Other Compensation$7,238
Exercisable Options889,150
Exercisable Options Value$3,357,338
Unexercisable Options231,250
Unexercisable Options Value$656,563
Total Value of Options$4,013,900
Total Number of Options1,120,400

Total Compensation*

Total Annual Cash Compensation$789,433
Total Short Term Compensation$504,195
Other Long Term Compensation$7,238
Total Calculated Compensation$1,478,488
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $10.91 USD -0.11

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$515.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
--
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director and Member of Strategic Operations Committee
Emergent BioSolutions, Inc.
$1.0M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.